SMO and leukemia: Preclinical studies found that PF-913, an inhibitor of SMO, can decrease the proportion of CD34+ leukemia cells, induce dormant LSCs into the cell cycle, reduce leukemia initiation, and exert synergistic effects with cytarabine (AraC) (41).